公开(公告)号：US20210246170A1

公开(公告)日：2021-08-12

申请号：US17163357

申请日：2021-01-30

申请人： Janssen Pharmaceuticals, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Johannes Petrus Maria LANGEDIJK ,  Lucy RUTTEN ,  Mark Johannes Gerardus BAKKERS ,  Rinke BOS ,  Frank WEGMANN ,  David Adrianus Theodorus Maria ZUIJDGEEST ,  Dan H. BAROUCH ,  An VANDEBOSCH ,  Mathieu Claude Michel le GARS ,  Jerald C. SADOFF

IPC分类号： C07K14/005 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86 ,  A61K39/215

摘要： The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

公开(公告)号：US20230075527A1

公开(公告)日：2023-03-09

申请号：US17759803

申请日：2021-01-30

申请人： Janssen Pharmaceuticals, Inc ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. BAROUCH ,  Johannes Petrus Maria LANGEDIJK ,  Lucy RUTTEN ,  Mark Johannes Gerardus BAKKERS ,  Rinke BOS ,  Frank WEGMANN ,  David Adrianus Theodorus Maria ZUIJDGEEST ,  An VANDEBOSCH ,  Mathieu Claude Michel LE GARS ,  Jerald C. SADOFF

IPC分类号： A61K39/215 ,  A61P31/14

摘要： The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

公开(公告)号：US20210388032A1

公开(公告)日：2021-12-16

申请号：US17387105

申请日：2021-07-28

申请人： Janssen Pharmaceuticals, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Johannes Petrus Maria LANGEDIJK ,  Lucy RUTTEN ,  Mark Johannes Gerardus BAKKERS ,  Rinke BOS ,  Frank WEGMANN ,  David Adrianus Thedorus Maria ZUIJDGEEST ,  Dan H. BAROUCH ,  An VANDEBOSCH ,  Mathieu Claude Michel le GARS ,  Jerald C. SADOFF

IPC分类号： C07K14/005 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86 ,  A61K39/215

摘要： The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

公开(公告)号：US20210346492A1

公开(公告)日：2021-11-11

申请号：US17317279

申请日：2021-05-11

申请人： Janssen Pharmaceuticals, Inc.

发明人： Jason DEHART ,  Christian MAINE ,  Brett Steven MARRO ,  Johannes Petrus Maria LANGEDIJK ,  Lucy RUTTEN ,  Mark Johannes Gerardus BAKKERS ,  Ronald VOGELS ,  Marijn VAN DER NEUT KOLFSCHOTEN ,  Aneesh VIJAYAN

IPC分类号： A61K39/215 ,  C07K14/165

摘要： RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.